Pragma Bio

Executive Summary

Pragma Bio is a San Diego-based biotechnology company founded in 2021 that leverages an AI-enabled, biology-first platform to discover novel small molecules derived from the human gut microbiome. By mining biosynthetic gene clusters (BGCs) from clinically-relevant microbial sources, the company targets the gut-immune axis for diverse therapeutic applications. Its approach aims to de-risk drug discovery by starting with naturally evolved, immune-modulating molecules, potentially offering a new class of drugs for inflammatory, autoimmune, and metabolic diseases. The company is in an early development stage and has not yet disclosed specific pipeline candidates or funding amounts. However, its platform has the potential to generate a rich pipeline of first-in-class molecules. Key upcoming milestones include raising a Series A round to advance lead programs, nominating a development candidate, and securing partnerships with larger pharmaceutical companies interested in microbiome-derived therapeutics. Pragma Bio's success will depend on validating its platform with preclinical proof-of-concept data and attracting investment in a competitive biotech landscape.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement70% success
• Q2 2026Lead Candidate Nomination60% success
• Q4 2026Pharma Partnership or Collaboration50% success